Moderna closed Wednesday at $174.38, up 176.97% on the session, the largest single-day move the stock has ever printed and one that took its market value from roughly $25B to about $70B in six and a half hours. The catalyst was a topline readout from INTerpath-001, the Phase 3 trial pairing its individualized mRNA therapy intismeran autogene with Merck’s Keytruda in melanoma patients whose tumors had been surgically removed. The trial hit its primary endpoint on recurrence-free survival and its key secondary endpoint on distant metastasis-free survival, making it the first Phase 3 success for any mRNA cancer therapy. Volume ran at 199.3 million shares against a three-month average of 9.6 million, so the move was not a thin-tape artifact. The read-through spread across the sector, with BioNTech up 21.96% and Merck adding more than 10%. What follows covers the trial data itself, the mechanics behind a move of this size, the platform case that justifies a $70B valuation, and the revenue base sitting underneath it.
The Read
- MRNA closed at $174.38, up 176.97%, on 199.3 million shares against a 9.6 million average.
- INTerpath-001 enrolled 1,137 stage IIB-IV melanoma patients and cleared both endpoints.
- Market value roughly tripled to about $70B on a 2025 revenue base of $1.94B.
A 1,137-Patient Melanoma Trial Cleared Both Endpoints
INTerpath-001 enrolled 1,137 patients with completely resected stage IIB to IV melanoma, the population at high risk of relapse after surgery. Each patient received either intismeran autogene plus Keytruda or Keytruda on its own. The combination arm delivered longer recurrence-free survival and a lower rate of spread to distant organs, which is the pair of readouts oncology buyers actually underwrite.
Two firsts sit inside that result. It is the first positive Phase 3 for an individualized neoantigen therapy, and the first for any mRNA-based cancer treatment. It is also the first Phase 3 to show a clinically meaningful improvement over Keytruda alone, which matters because Keytruda is the incumbent standard of care rather than a soft comparator. The two companies laid out the endpoints in the joint statement they issued on the topline results.
The Phase 2b groundwork had already pointed this direction, with a 49% reduction in the risk of recurrence or death at five years. The bull reading is that the Phase 3 converted a promising mid-stage signal into a registrational one. The bear reading is that topline language confirms direction without publishing hazard ratios, confidence intervals or the safety profile, and the gap between met and quantified is where repricings unwind.
199 Million Shares Traded Against a 9.6 Million Average
Turnover in Moderna ran 1,819% above the three-month average, which tells you the move was not made by long-only holders adding on conviction. A stock that opens more than 100% higher forces every short and every hedged options book to cover into an offer that has effectively disappeared, and that mechanic supplies its own demand for several hours.
The intraday path is worth holding onto. The stock traded near $129.24 in the first hour, up around 105%, and finished at $174.38. Buyers kept paying up through the whole session rather than fading the open, which is the pattern that separates a genuine re-rating from a squeeze that mean-reverts within a week.
Sector spillover confirms the platform read rather than a single-name story. BioNTech closed at $113.12, up 21.96%, and Pfizer at $28.25, up 3.69%, while Merck gained more than 10% as the partner holding the Keytruda side. That said, the index backdrop was flat, with the S&P 500 at 7,708 and the Nasdaq Composite at 26,331, both up around 0.2%. This was an idiosyncratic event, not a risk-on tape.
The Platform Read That Argues for a $70B Cap
The optionality argument is straightforward. Intismeran is not one drug, it is the first validated output of an individualized neoantigen pipeline, and the same manufacturing and sequencing stack feeds multiple Phase 2 and Phase 3 oncology programs already running. One positive Phase 3 de-risks the platform, not just the melanoma indication. The melanoma population is also the smallest prize on that list, which is precisely why the market did not price it as a melanoma result.
That framing is what took the market value from roughly $25B to about $70B in a session. The market is pricing the probability that a second and third indication now read out positively, at a discount rate that just fell hard. Repricing a pipeline is faster than repricing a product, which is why the move was so violent.
There is a sector precedent worth keeping in view. AstraZeneca’s quarter, carried by a 15% jump in cancer drug sales, showed how quickly oncology franchises compound once approval lands. Novartis printing $5.9B in core operating profit is the same lesson at scale. Both are what a validated Moderna oncology franchise could look like several years out, and both took years of commercial execution to get there.
A $1.94B Revenue Base Under a $70B Valuation
The fundamentals underneath this move are severely impaired. Moderna posted $1.94B of revenue in 2025, down about 90% from $19.26B in 2022, with revenue still contracting at 27.6%. The company is loss-making at the gross line, with a gross margin of -105.8% and a net margin of -145.2%, and 2025 earnings per share came in at -$7.25.
So the valuation now rests almost entirely on a readout that has no approval, no label, no launch date and no disclosed pricing. A topline release is not a regulatory filing. Between here and revenue sit full data publication, submission, review and a commercial build for a therapy manufactured individually per patient, which is an operationally harder problem than shipping a vial.
Positioning is the near-term risk. A daily RSI at 87.7 leaves the stock deeply extended, and the chart offers little underneath before $115 to $117, then $100 to $105. The pattern where a genuine beat still gets sold is well documented, and Datadog falling 19% after beating and raising is the reminder that good news bought at the wrong level is still a bad entry.
The asymmetry an investor has to price is therefore uncomfortable in both directions. A confirmed hazard ratio at a medical conference re-rates the platform again and makes $174 look early. A thin dataset, a safety signal or a slow regulatory path leaves a company with $1.94B of shrinking revenue carrying a $70B market value, and that gap closes downward far faster than it opened.
More to come.
About the Author
